Capricor Therapeutics (NASDAQ:CAPR) Rating Reiterated by Oppenheimer

Oppenheimer reaffirmed their outperform rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a research report report published on Monday, Benzinga reports. The brokerage currently has a $15.00 price objective on the biotechnology company’s stock.

Other research analysts have also issued reports about the company. Cantor Fitzgerald reiterated an overweight rating and issued a $8.00 price objective on shares of Capricor Therapeutics in a research report on Friday. Maxim Group reiterated a buy rating and issued a $12.00 price objective on shares of Capricor Therapeutics in a research report on Tuesday, September 17th. Finally, HC Wainwright reiterated a buy rating and issued a $40.00 price objective on shares of Capricor Therapeutics in a research report on Tuesday, September 17th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of Moderate Buy and an average price target of $20.00.

Capricor Therapeutics Price Performance

NASDAQ CAPR opened at $5.97 on Monday. The firm has a market cap of $190.91 million, a PE ratio of -6.86 and a beta of 3.92. Capricor Therapeutics has a one year low of $2.68 and a one year high of $7.28. The stock’s 50 day simple moving average is $4.39 and its 200 day simple moving average is $5.19.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). The business had revenue of $3.97 million for the quarter, compared to the consensus estimate of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. As a group, equities analysts expect that Capricor Therapeutics will post -1.24 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CAPR. Jump Financial LLC bought a new position in shares of Capricor Therapeutics in the 4th quarter worth $258,000. BNP Paribas Financial Markets bought a new position in shares of Capricor Therapeutics in the 1st quarter worth $40,000. Vanguard Group Inc. boosted its position in shares of Capricor Therapeutics by 17.2% in the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock worth $9,274,000 after purchasing an additional 200,499 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Capricor Therapeutics by 12.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after purchasing an additional 9,040 shares during the last quarter. Finally, Rhumbline Advisers bought a new position in shares of Capricor Therapeutics in the 2nd quarter worth $147,000. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.